Holen Sie sich die Stockscreener-App
17.24
10.81%
-2.09
Handel nachbörslich:
17.45
0.21
+1.22%
Schlusskurs vom Vortag:
$19.33
Offen:
$18.7
24-Stunden-Volumen:
51.24M
Relative Volume:
2.41
Marktkapitalisierung:
$3.92B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
24.99
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-32.50%
1M Leistung:
-45.60%
6M Leistung:
-66.81%
1J Leistung:
-61.49%
1-Tages-Spanne:
$17.20
$19.38
1-Wochen-Bereich:
$16.35
$27.77
52-Wochen-Spanne:
$16.35
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
17.24 | 4.40B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.10 | 56.01B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.13 | 56.10B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.04 | 48.45B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.37 | 39.65B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.20 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Meet The Attys For Novo Nordisk In Hims & Hers GLP-1 Row - Law360
Legal pressures mount for Hims & Hers over GLP-1 sales - The Hill
Novo Nordisk Takes On Hims Over Copycat GLP-1 Pill - Law360
Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - Finviz
Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary
Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Palmetto Grain Brokerage - Palmetto Grain Brokerage
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Yahoo Finance
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent
Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com
Novo Nordisk, maker of Ozempic, sues over weight loss drug copycats - NewsNation
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Purchased by Candriam S.C.A. - MarketBeat
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny - TechStock²
Hims And Hers Retreats On GLP1 Pills As Legal And Regulatory Risks Grow - Yahoo Finance UK
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide - Yahoo Finance Singapore
The Knockoff GLP-1 Market Is Still the Wild West - Bloomberg
Hims & Hers retreats from compounded GLP-1 pill - Axios
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies - Yahoo Finance
Why Hims Stock Slid 40% In A Month? - Forbes
Hims built a boundary-pushing health business. Now the legal risks are catching up. - Sherwood News
Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure - Morningstar Canada
Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA - Trefis
‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts - TipRanks
Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny - Optometry Advisor
Stocks to Watch Monday Recap: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit - Yahoo Finance
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit - The Motley Fool
Novo Nordisk going forward with suit against Hims & Hers despite it scrapping plans to sell copycat Wegovy pill - The Boston Globe
Hims & Hers Health: Don’t Fall For The Hysteria (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novo Nordisk sues hims & hers over Ozempic, Wegovy knockoffs - cbsnews.com
Stock Movers: Applovin, Oracle, Hims & Hers Health - Bloomberg
Hims & Hers Stock Plunges 16%. Its Weight-Loss Drug Strategy Backfired. - Barron's
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? - Yahoo Finance
Stock Movers: Oracle, Kyndryl, Hims & Hers Health - Bloomberg
Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More Movers - Barron's
Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1 - Law360
Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds - Yahoo Finance
Novo Nordisk Escalates Fight Against Hims & Hers - The Wall Street Journal
Novo Nordisk Sues Hims & Hers Over Ozempic Copycats as the Weight-Loss Drug Wars Escalate - Gizmodo
Novo says it’s suing Hims to halt obesity GLP-1 drug copycats - Orange County Register
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Key facts: Hims & Hers Health stock drops; DOJ probes weight-loss meds; lawsuit criticized - TradingView
Novo Nordisk sues Hims after $49 weight-loss pill sparks FDA backlash - Yahoo Finance UK
Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout' - Seeking Alpha
FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast - Benzinga
Novo Nordisk says it’s suing Hims to halt obesity drug copycats - Ad Age
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):